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Abstract
The major potential adverse effect of use of sulfonylurea agents
(SUAs) is a hyperinsulinaemic state that causes hypoglycaemia. It
may be observed during chronic therapeutic dosing, even with very
low doses of a SUA, and especially in older patients. It may also
result from accidental or intentional poisoning in both diabetic and
nondiabetic patients. The traditional approach to SUA-induced
hypoglycaemia includes administration of glucose, and glucagon or
diazoxide in those who remain hypoglycaemic despite repeated or
continuous glucose supplementation. However, these antidotal
approaches are associated with several shortcomings, including
further exacerbation of insulin release by glucose and glucagon,
leading only to a temporary beneficial effect and later relapse into
hypoglycaemia, as well as the adverse effects of both glucagon
and diazoxide. Octreotide inhibits the secretion of several
neuropeptides, including insulin, and has successfully been used
to control life-threatening hypoglycaemia caused by insulinoma or
persistent hyperinsulinaemic hypoglycaemia of infancy. Therefore,
this agent should in theory also be useful to decrease glucose
requirements and the number of hypoglycaemic episodes in
patients with SUA-induced hypoglycaemia. This has apparently
been confirmed by experimental data, one retrospective study
based on chart review, and several anecdotal case reports. There
is thus a need for further prospective studies, which should be
adequately powered, randomized and controlled, to confirm the
probable beneficial effect of octreotide in this setting.
Introduction
Although the number of oral medications available to treat
diabetes mellitus has increased, sulfonylurea agents (SUAs)
remain a mainstay of therapy for hyperglycaemia in type 2
diabetes. The major potential adverse effect of use of SUA is
a hyperinsulinaemic state that causes hypoglycaemia. It may
be observed during chronic therapeutic dosing, even with
very low doses of a SUA, and especially in older patients. It
may also result from accidental or intentional poisoning in
both diabetic and nondiabetic patients [1].
The traditional approach to SUA-induced hypoglycaemia
includes the administration of glucose, and glucagon or
diazoxide in those who remain hypoglycaemic despite
repeated or continuous glucose supplementation [2,3].
However, these antidotal approaches are associated with
several shortcomings, including further exacerbation of insulin
release by glucose and glucagon, leading only to a temporary
beneficial effect and later relapse into hypoglycaemia [3], as
well as the adverse effects of both glucagon and diazoxide
[2,4]. Other measures that have been proposed include
corticosteroids and urinary alkalinization to enhance urinary
elimination of the SUA (e.g. chlorpropamide) [5], but their
usefulness has not clearly been established.
Octreotide inhibits the secretion of several neuropeptides,
including insulin, and has been successfully used to control
life-threatening hypoglycaemia caused by insulinoma [6,7] or
persistent hyperinsulinaemic hypoglycaemia of infancy [7,8].
Therefore, this agent should in theory also be useful to
decrease glucose requirements and the number of hypo-
glycaemic episodes in patients with SUA-induced hypo-
glycaemia – effects that are related to the hyperstimulation of
endogenous insulin production. This hypothesis has been
evaluated in a few studies and clinical case reports, and
these are reviewed here.
Pharmacology of octreotide
Octreotide acetate (Sandostatine®; Novartis Pharma, Basel,
Switzerland) is a synthetic analogue of the natural hormone
somatostatin that is able to bind to the same receptors. The
molecular weight of this cyclic octapeptide is 1019.3, and
binding of octreotide to plasma protein is about 65%.
Octreotide has effects similar to those of somatostatin but
with greater potency and longer duration of action; these
effects include inhibition of pituitary release of growth
hormone and thyrotropin, inhibition of glucagon or insulin
release, and inhibition of the secretion of various gastro-
intestinal tract hormones (e.g. serotonin, pepsin, gastrin,
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secretin, motilin, vasoactive intestinal peptide and pancreatic
peptides) [9,10]. Furthermore, it overcomes some of the
shortcomings of exogenous somatostatin, namely a need for
intravenous administration, a short duration of action, and a
postinfusion rebound of hormonal secretion [10].
Octreotide is clinically used to suppress excessive growth
hormone secretion in acromegaly, to inhibit thyrotropin-
secreting pituitary adenomas (thyrotrophinomas), and to treat
flushing and diarrhoea associated with certain gastro-
enterological or pancreatic neuroendocrine tumours, especially
carcinoid tumors and pancreatic islet cell tumors
(insulinomas), which produce a variety of peptide hormones
and biogenic amines [10-12]. Trials in patients with tumours
producing vasoactive intestinal peptide demonstrated that
octreotide may be an effective first-line treatment for this
condition. Octreotide has also been used to control bleeding
oesophageal varices; to treat chronic secretory diarrhoea
associated with cryptosporidiosis, microsporidiosis and
intestinal amoebiasis; to reduce the output of small bowel
fistulas [13] and pancreatic pseudocyst drainage [14]; and to
obtain relief from dumping syndrome after gastric surgery
[15,16].
For these indications the initial dose is usually 50 µg, which is
injected subcutaneously once or twice daily. The number of
injections and dosage may then be increased gradually (from
300 to 600 µg, divided into two or three daily doses) based
on tolerance and response.
After subcutaneous injection, octreotide is absorbed rapidly
and completely from the injection site. Peak concentration in
plasma is reached after 15–30 min. Bioavailability (peak
concentration, area under the curve) has been shown to be
equivalent with intravenous and subcutaneous administra-
tion. In healthy volunteers the distribution of octreotide from
plasma is rapid (half-life = 0.2 h) and the volume of
distribution is  estimated to be 13.6 l; also, 60–65% of
octreotide is bound to plasma proteins. In blood, the
distribution into erythrocytes was found to be negligible, and
about 65% was bound in the plasma in a concentration-
independent manner. Binding was mainly to lipoprotein and,
to a lesser extent, to albumin.
Elimination of octreotide from plasma had an apparent half-
life of 1.5 hours, as compared with 1–3 min with the natural
hormone somatostatin. The duration of action of octreotide is
variable but may extend up to 12 hours, depending on the
type of tumour. Total body clearance is high (10 l/hour) but is
markedly reduced in renal failure. About 11% of the dose is
excreted unchanged in urine. Octreotide may be at least
partly metabolized by liver, but the effect of hepatic disease
on this is unknown. Dosage adjustments may be necessary in
the elderly because of a significant increase in half-life (46%)
and a significant decrease in clearance (26%) of the drug
[12].
Octreotide appears to be well tolerated. The most frequently
reported adverse effects are moderate pain at the injection
site and gastrointestinal symptoms (abdominal cramps,
nausea, bloating, flatulence, diarrhoea). Like somatostatin,
long-term administration of octreotide appears to promote the
formation of cholelithiasis [10,12,17].
Other analogues of somatostatin are currently under
development [10] and indium-111 or yttrium-90 radiolabelled
somatostatin analogues have been use as diagnostic and/or
therapeutic agents in patients with extensive liver metastases
from neuroendocrine tumours [18-20].
Pharmacology and toxicology of sulfonylurea
agents
SUAs act by reducing potassium conductance of an ATP-
dependent potassium channel, thereby decreasing potassium
ion efflux, stimulating the depolarization of pancreatic β cells
and leading to calcium influx through voltage-sensitive
calcium channels. The elevated intracellular concentration of
calcium ions increases the sensitivity of β cells to glucose.
The resultant effect of SUAs is thus to promote glucose-
stimulated endogenous insulin secretion (exocytosis) from the
pancreas [21-23]. In addition, there is evidence that SUA can
inhibit hepatic clearance of insulin – an effect that also
contributes to hyperinsulinaemia. On the other hand, hyper-
insulinaemia suppresses endogenous (predominantly hepatic)
glucose production. Therefore, the main toxic effect of SUA is
hypoglycaemia [24]. Differences in pharmacokinetic
characteristics (duration of action, hepatic metabolism and/or
renal excretion, enterohepatic circulation, active metabolites)
may have important implications for the severity and duration
of SUA-induced hypoglycaemia [24].
Serious hypoglycaemia is usually defined as hypoglycaemia
that causes death or that requires prehospital team inter-
vention, hospitalization, or emergency department admission.
The annual incidence of SUA-induced hypoglycaemia is
probably about 1–2% of SUA-treated patients [25]. Case
fatality rates of up to 10% have been reported [26], and 5%
of survivors may have permanent neurological impairment
[27]. Unfortunately, the prognostic factors of death or brain
sequelae are not known. Predisposing factors for severe
SUA-induced hypoglycaemia include advanced age [28,29]
and use of potent or long-acting agents such as chlorpro-
pamide, glimepiride and (mostly) glibenclamide [29,30].
Severe hypoglycaemia leading to hospital admission and
sometimes fatal outcome has mainly been reported in the
settings of overdose and type 2 diabetes managed with long-
acting rather than short-acting SUAs [30-33]. Poor nutritional
status or calorie restriction, sustained physical exercise,
acute systemic illnesses, alcohol consumption, and renal,
hepatic and cardiovascular disease [24,34,35] are other risk
factors for development of severe hypoglycaemia. In the
elderly the clinical presentation of SUA-induced hypo-545
glycaemia may be atypical, and so a high index of suspicion is
required; moreover, even shorter acting SUAs can cause
hypoglycaemia, especially if renal or hepatic dysfunction is
present. Polypharmacy also increases the risk for hypo-
glycaemia in the elderly, either by direct pharmacokinetic
interaction (binding sites on plasma proteins, or impairment in
hepatic metabolism or renal excretion) or by effects on
appetite, food intake, or carbohydrate absorption [24,36].
Other relevant metabolic problems that may be observed in
long-acting SUA intoxication include hypokalaemia and
hypophosphataemia. Chlorpropamide has been associated
with specific toxic effects including hyponatraemia due to
inappropriate secretion of antidiuretic hormone, cholestatic
jaundice and bone marrow depression.
Traditional treatment of sulfonylurea 
agent-induced hypoglycaemia
The traditional approach to SUA overdose includes repeated
measurement of blood glucose levels, every 20–60 min, and
infusion of hypertonic glucose as needed. Indeed, hypo-
glycaemia can be prolonged and may recur during a period of
more than 24–48 hours despite glucose supplementation.
Hypertonic glucose infusion rapidly corrects hypoglycaemia,
but it then acts as a potent secretagogue for SUA-sensitized
β cells; insulin secretion is stimulated, and so the hypo-
glycaemia recurs [37-40]. This effect is particularly important
in nondiabetic persons, non-insulin-dependent diabetic
patients and those not previously treated with SUAs [23].
Therefore, central venous access is often required for
continuous and prolonged infusion of hypertonic glucose,
and frequently repeated measurement of blood glucose level
is mandatory; strict euglycaemia should be the goal and hyper-
glycaemia, as well as hypoglycaemia, should be avoided [3].
Apart from glucose administration, two antidotal approaches
to SUA overdose have been employed, one using glucagon
and the other diazoxide. Glucagon has been shown to
produce only transient beneficial effects on glycaemia.
Indeed, it also dramatically stimulates the release of
endogenous insulin and thereby contributes to subsequent
hypoglycaemia [3,41]. Diazoxide, an antihypertensive agent,
acts as a potassium channel opener and has been used to
reduce insulin release and limit rebound hypoglycaemia [2,3],
but its efficacy appears limited [39]. It must be administered
by intravenous infusion and its use could be associated with
hypotension, reflex tachycardia, nausea and vomiting
[2,4,42]. Such adverse effects may be especially problematic
in elderly patients.
Octreotide in sulfonylurea agent-induced
hypoglycaemia: experimental and clinical
data
Animal and volunteer studies
Few animal and volunteer human studies have examined the
effects of somatostatin or octreotide on SUA-induced
hypoglycaemia. These have demonstrated the short-term
inhibitory effect of somatostatin on insulin release during
glucose infusion or tolbutamide administration [43,44].
Compared with somatostatin, octreotide is expected to
confer at least an equal inhibitory effect on insulin release but
with a longer duration of action. This was confirmed in a
controlled randomized crossover study [39]. Eight healthy
volunteers were given glipizide orally (1.45 mg/kg) on 3
separate days. All volunteers developed hypoglycaemia
(glucose concentration <50 mg/dl) within 3 hours. They were
initially treated with 25 g of 50% glucose. Then, the treatment
consisted of the following: glucose infusion alone to maintain
euglycaemia (glucose concentration 85 mg/dl; treatment limb
1); same as treatment limb 1 plus continuous intravenous
octreotide (30 ng/kg per min; treatment limb 2); or same as
treatment limb 1 plus intravenous diazoxide every 4 hours
(300 mg; treatment limb 3). Octreotide infusion significantly
lowered insulin levels as compared with treatment limbs 1
and 3 (P < 0.01). Glucose requirements to reach
euglycaemia in treatment limbs 1 and 3 were similar but
greater than those with octreotide treatment (P < 0.001).
When therapy was stopped 13 hours after glipizide ingestion,
only two out of eight volunteers developed hypoglycaemia
within 4 hours after therapy with octreotide, whereas all
inidividuals in treatment limbs 1 and 3 had rebound hypo-
glycaemia within 90 min. Overall, octreotide reduced the need
for exogenous glucose (in four out of eight it was entirely
eliminated) in this clinical model of glipizide overdose,
demonstrating the prolonged suppressive action of octreotide
on glucose-stimulated insulin secretion by SUA-sensitized β
cells.
Clinical data
Although SUA-induced hypoglycaemia remains an unlicenced
indication, several authors have reported successful use of
octreotide in patients with SUA overdose, and this clinical
experience seems to confirm the clinical antidotal value of this
agent [3,38,45-55].
In 1993 Krentz and coworkers [38] reported on a nondiabetic
patient with SUA-induced hypoglycaemic coma, who
relapsed despite resuscitation with intravenous boluses of
50% glucose and continuous 10% glucose infusion.
Subcutaneous injection of octreotide (50 µg every 12 hours;
three doses over 24 hours) prevented further recurrence of
hypoglycaemia such that no further bolus of 50% glucose
was needed. No adverse effects were observed.
Boyle and colleagues [39] reported the case of a 36-year-old
male who attempted suicide with a large overdose of
tolbutamide. Initial therapy with dextrose resulted in repeated
hypoglycaemia. A regimen of octreotide administration similar
to that reported by Krentz and coworkers allowed
euglycaemia to be maintained, without need for additional
dextrose support, by decreasing plasma insulin and C-
peptide levels. Several other isolated reports have also
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confirmed the clinical value of octreotide in patients with
severe refractory SUA-induced hypoglycaemia [45,48,56].
Graudins and coworkers [3] reported an interesting case of a
42-year-old nondiabetic man who attempted suicide on two
separated occasions by ingesting 150 mg glipizide. On the
first occasion he was treated only with glucose and required
1511 g glucose over a 72-hour period to treat recurrent
hypoglycaemia. On the second occasion, 50 µg octreotide
was administered subcutaneously at 2 hours after ingestion
of glipizide, followed by 100 µg at 8, 20 and 32 hours after
ingestion. Only 826 g glucose had to be administered on the
second occasion. Octreotide administration was associated
with a marked reduction in serum insulin levels.
The largest (although relatively small) retrospective obser-
vational series was that reported by McLaughlin and
colleagues [49]. They reviewed the charts of nine adult
patients treated with octreotide for SUA-induced hypo-
glycaemia (six had ingested gliburide and three had ingested
glipizide) from 1995 to 1998. Octreotide (ranging from a
single subcutaneous dose of 40 µg to an intravenous infusion
of 125 µg/hour) significantly reduced the number of hypo-
glycaemic events recorded per patient from a mean of 3.2
before administration to a mean of 0.2 after (P = 0.008). The
amount of 50% glucose ampoules used per patient was also
markedly reduced (from a mean of 2.9 before to 0.2 after;
P = 0.004), although the maintenance glucose infusion rate
was similar. This stabilization of blood glucose concentration
occurred immediately after octreotide administration in all
nine patients. Two treatment failures were observed, defined
as occurrence of hypoglycaemia 14 hours after octreotide
administration (and 30 hours after the ingestion of glyburide)
and 36 hours after octreotide (40 hours after ingestion of
extended release glipizide), respectively. It is likely that more
prolonged administration of octreotide would have prevented
relapsing hypoglycaemia.
Carr and Zed [51] reported on the use of octreotide in the
management of two cases of SUA-induced hypoglycaemia
following overdose in two young women (500 mg and 1 g
gliburide, respectively). Despite administration of bolus doses
of glucose 50% and infusions of glucose 10%, both patients
exhibited refractory hypoglycaemia. Three doses of octreotide
50 µg were administered subcutaneously, 8 hours apart, to
both patients, resulting in a reduction in hypoglycaemic
episodes and reduced need for dextrose administration.
Nzerue and coworkers [52] reported the case of a patient
with chronic renal failure who developed recurrent and
prolonged episodes of hypoglycaemia associated with the
use of SUA. He was hospitalized with neuroglycopenic
symptoms that persisted in spite of large doses of parenteral
glucose. On administration of octreotide, the hypoglycaemia
resolved and blood glucose levels were maintained even after
cessation of parenteral glucose. Only two subcutaneous
doses of octreotide 12 hours apart were needed, and the
patient fully recovered.
Green and Palatnik [53] reported the case of a 20-year-old
woman who ingested 900 mg gliburide, causing hypo-
glycaemia that was refractory to treatment with intravenous
glucose, glucagon, and diazoxide. Octreotide administration
(100 µg intravenously) rapidly reversed the hypoglycaemia,
stabilizing the patient and permitting eventual discharge
without significant adverse events.
More recently, successful management of SUA-induced
refractory hypoglycaemia with octreotide was reported by
Crawford and Perera [55] in two elderly patients. A 76-year-
old man with type 2 diabetes controlled with gliclazide 80 mg
twice daily was admitted after an acute myocardial infarction
and cardiac arrest. He was successfully resuscitated and
underwent emergency bypass surgery, but developed
cardiac and renal failures. Frequent and refractory hypo-
glycaemic episodes were observed, associated with seizures
and coma, in spite of gliclazide discontinuation and intra-
venous infusion of glucose 10%. An intravenous infusion of
octreotide (30 ng/kg per min) was associated with rapid
control of blood glucose level, but the infusion had to be
maintained for 13 hours. The patient was discharged home
2 days later. A 75-year-old man with type 2 diabetes taking
glibenclamide 2.5 mg/day developed recurrent
hypoglycaemia associated with impaired renal function.
Hypoglycaemic coma occurred despite glibenclamide
discontinuation and repeated supplementation with
intravenous boluses of glucose 50% and continuous infusion
of glucose 10%. The high volume of intravenous fluid
precipitated cardiac failure and pulmonary oedema, requiring
inotropic support. A single subcutaneous injection of 50 µg
octreotide was administered. One hour later the blood
glucose level was normalized and no further episodes of
hypoglycaemia occurred. In this case, marked reductions in
insulin and C-peptide levels were documented (before
octreotide treatment: insulin 1250 pmol/l and C-peptide
20,949 pmol/l; 8 hours after octreotide treatment: insulin
153 pmol/l and C-peptide 5654 pmol/l). The patient fully
recovered.
Only two cases of antidotal use of octreotide have been
reported in children [47,54]. A 5-year-old child was
erroneously given glipizide in repeated doses over 3 days
[47]. He was admitted in status epilepticus and his blood
glucose was 12 mg/dl. The seizures stopped after lorazepam
was given, but recurrent hypoglycaemia developed despite
glucose supplementation (up to 18 g/hour). A 25 µg
(1.25 µg/kg in this 20 kg child) dose of octreotide was
administered intravenously and resulted in a rapid increase in
glycaemia to 150–200 mg/dl, thereby allowing the amount of
glucose adminisered to be reduced and completely stopped
4 hours later. A marked decrease in insulin concentration was
also documented after octreotide administration in this case
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(before octreotide treatment: insulin 53 µUI/ml and blood
glucose 45 mg/dl; after octreotide treatment: insulin
16 µUI/ml and blood glucose 183 mg/dl). A 16-month-old
child (weight not reported) was admitted 1 hour after
ingesting glyburide accidentally [54]. Despite continuous
infusion of 10% dextrose and repeated boluses of 50%
glucose, recurrent hypoglycaemia developed. Approximately
5 hours after ingestion, he received 10 µg octreotide
intravenously over 15 min. Euglycaemia was then maintained
with 10% glucose infusion, without any additional bolus. A
second dose of octreotide had to be given 8 hours later.
Glucose 10% infusion was completely stopped 5 hours after
the second octreotide injection.
This clinical experience suggests that octreotide is effective
in treating prolonged or refractory hypoglycaemia induced by
SUA, as well as in preventing rebound hypoglycaemia by
breaking the vicious circle that can result from glucose
supplements and consequent insulin release. It should be
used in adults [57] as well as in children [58-60], despite the
limited clinical experience.
Route and dosage
There is clinical experience with both subcutaneous and
intravenous administration. Octreotide has most frequently
been administered subcutaneously in doses ranging from 40
to 100 µg in adults. The most commonly used regimen
consists of an initial 50 µg dose, which is repeated two to
three times a day. Doses ranging from 1 to 10 µg/kg have
been well tolerated by children in other conditions [58].
Intravenous administration usually consists of a continuous
infusion (30  ng/kg per min). In a paediatric case, a 25 µg
intravenous dose was used in a 20 kg child [47].
Bioavailability of both routes appears to be similar, but
subcutaneous injection seems to increase markedly the
duration of action [61].
Octreotide administration may be required for several days,
especially for long-acting or sustained release SUAs.
However, in the majority of reported cases, a treatment
course limited to 12–72 hours was needed to resolve the
hypoglycaemia. Because some patients experience delayed
hypoglycaemia after cessation of octreotide therapy, they
should be observed for rebound hypoglycaemia for at least
12–24 hours after the last dose [39].
Adverse effects
Treatment with octreotide appears to be safe and is usually
well tolerated. In nontoxicological indications such as
acromegaly or insulinoma, octreotide has been associated
with various adverse effects, including nausea, diarrhoea,
abdominal cramps and flatulence, especially at the beginning
of the treatment [10]. These symptoms result from the
physiological actions of somatostatin on the gastrointestinal
tract and exocrine pancreas, and begin within hours after the
first injection. Their severity is dose dependent [10]. Reduced
glucose tolerance and hyperglycaemia that might be
expected is limited with long-term therapy by the ability of
octreotide to delay absorption of carbohydrate and to inhibit
the secretion of growth hormone and glucagons. Long-term
treatment with octreotide (>1 month) has been associated
with an increased incidence of cholesterol gallstones
(occurring in approximately 20–30% of patients).
When it is used to counteract SUA-induced hypoglycaemia,
both in chronic and acute overdose, complications appear
very few and mortality is nil. Rare reported adverse effects
include injection site pain, nausea, vomiting, dose-related
transient abdominal pain and diarrhoea [39].
Economical considerations
Octreotide is not currently licenced for the indication of SUA-
induced hypoglycaemia. Depending on local regulations, this
may prevent reimbursement of its cost by social insurance
agencies.
Although it would not be expected to reduce mortality and
long-term morbidity rates markedly compared with a carefully
monitored glucose infusion, octreotide does have some
advantages. For example, it renders the management of SUA-
poisoned patients easier. The treatment is also economical
because octreotide is inexpensive (costing less than €10 for
a 100 µg vial) and it potentially reduces the need for frequent
glucose measurements, insertion of central line access or
intensive care unit admission.
These advantages may be particular prominent in elderly
people. Indeed, the classical autonomic adrenergic
symptoms and signs of hypoglycaemia may not be present,
and neuroglycopenic features, such as drowsiness and
confusion, may dominate the clinical picture. The diagnosis
can be easily missed if the blood glucose level is not
frequently monitored. In addition, intravenous glucose
replacement may carry a risk for fluid overload in those
patients who often suffer impairment in cardiac or renal
function, and so close observation of haemodynamic
parameters in the intensive care unit setting is mandatory.
It is unwise to discharge patients with SUA-induced
hypoglycaemia after a satisfactory initial response. Indeed,
both intravenous glucose supplements and subcutaneous
octreotide administration may be required for several days.
Therefore, the hospital stay is not likely to be shortened,
whatever the treatment option.
Conclusion
Few experimental data are currently available on the use of
octreotide in SUA-induced hypoglycaemia. The reported
clinical experience, which is limited to one retrospective study
based on chart review, and several anecdotal case reports
may clearly be biased. There is thus a need for further
prospective studies, which should be adequately powered,
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randomized and controlled, to confirm the beneficial effect of
octreotide in this setting.
From available data, however, octreotide appears to be highly
efficacious and safe in the management of SUA-induced
hypoglycaemia. It should be considered, along with glucose
supplementation and gastrointestinal decontamination, for
first-line therapy in any patient with SUA-induced
hypoglycaemia, either symptomatic or with a serum glucose
concentration less than 60 mg/dl, especially if hypoglycaemia
is refractory to glucose supplementation or relapses.
The following scheme is recommended:
• Glucose 15–25 g must be delivered immediately as intra-
venous 50% glucose to restore the patient to eugly-
caemia in the short term (0.5 g/kg as intravenous 25%
glucose in children); oral glucose may be an alternative in
fully conscious and cooperative patients.
• The glucose bolus must be followed immediately by an
infusion of 5% or 10% glucose, usually at a rate of
100–200 g/day glucose.
• Blood glucose should be regularly monitored for at least
24 hours; the blood glucose concentration should be
maintained at around 90–120 mg/dl because this is
sufficient to prevent neuroglycopenia while avoiding
maximal insulin secretion.
• Potassium concentration should be also be monitored
(there is a risk for hypokalaemia with insulin and glucose).
• Gastrointestinal tract decontamination, especially
administration of activated charcoal, may be considered if
drugs have recently been ingested, in accordance with
usual recommendations.
• Methods to enhance elimination are usually not applicable.
However, multiple dose activated charcoal may be
considered for certain SAUs (e.g. glipizide) because of the
enterohepatic recirculation, although clinical benefit has
not been demonstrated. It has also been suggested that
urine alkalinization reduces the half-life of chlorpropamide.
• Octreotide (adults: 50 µg subcutaneously every 8–12 hours;
children: 1–1.25 µg/kg) is recommended if hypogly-
caemia relapses in spite of continuous glucose infusion.
Alternatively, octreotide could be used to prevent relapse
of hypoglycaemia; to reduce glucose requirements and
fluid administration, especially in elderly patients with
cardiac dysfunction or impaired renal function; or to
obviate the need to insert a central venous line access for
prolonged infusion of more concentrated hypertonic
glucose solutions, especially in children.
• If octreotide is not available, then diazoxide (aduilts:
300 mg intravenously over 30 min every 4 hours; children
[recommended but not supported by clinical experience]:
3–8 mg/kg per day orally divided into two to three doses
[i.e. every 8–12 hours]) remains a viable alternative to
reduce insulin secretion. However, it should be used
cautiously in elderly patients or those with coronary heart
disease because of its cardiovascular adverse effects.
• Glucagon should not be used in the management of SUA-
induced hypoglycaemia because it further stimulates
insulin secretion dramatically.
As mentioned above, continuing research is required to
confirm the clinical findings that support these provisional
recommendations, and to establish the optimal route and
dosing guidelines, dosing interval, duration of treatment and
inpatient monitoring requirements. Because recruitment of
large series of patients with SUA-induced hypoglycaemia in a
single centre is almost impossible, only a multicentre
approach will be able to answer these questions.
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